BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23052696)

  • 1. A nine-gene signature predicting clinical outcome in cutaneous melanoma.
    Brunner G; Reitz M; Heinecke A; Lippold A; Berking C; Suter L; Atzpodien J
    J Cancer Res Clin Oncol; 2013 Feb; 139(2):249-58. PubMed ID: 23052696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
    Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li W; Li J; Xiao Y
    PLoS One; 2020; 15(10):e0240331. PubMed ID: 33031392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
    Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
    J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
    Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
    J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort.
    Nsengimana J; Laye J; Filia A; Walker C; Jewell R; Van den Oord JJ; Wolter P; Patel P; Sucker A; Schadendorf D; Jönsson GB; Bishop DT; Newton-Bishop J
    Oncotarget; 2015 May; 6(13):11683-93. PubMed ID: 25871393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma.
    Amaral TMS; Hoffmann MC; Sinnberg T; Niessner H; Sülberg H; Eigentler TK; Garbe C
    Eur J Cancer; 2020 Jan; 125():38-45. PubMed ID: 31838403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma.
    Thakur R; Laye JP; Lauss M; Diaz JMS; O'Shea SJ; Poźniak J; Filia A; Harland M; Gascoyne J; Randerson-Moor JA; Chan M; Mell T; Jönsson G; Bishop DT; Newton-Bishop J; Barrett JH; Nsengimana J
    Clin Cancer Res; 2019 Dec; 25(24):7424-7435. PubMed ID: 31515461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Prognostic Gene Signature Expressed in Primary Cutaneous Melanoma: Synergism With Conventional Staging.
    Brunner G; Heinecke A; Falk TM; Ertas B; Blödorn-Schlicht N; Schulze HJ; Suter L; Atzpodien J; Berking C
    JNCI Cancer Spectr; 2018 Jul; 2(3):pky032. PubMed ID: 31360859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
    Keller J; Schwartz TL; Lizalek JM; Chang ES; Patel AD; Hurley MY; Hsueh EC
    Cancer Med; 2019 May; 8(5):2205-2212. PubMed ID: 30950242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
    Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
    BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Identification and Validation of a Robust Immune-Associated Gene Signature in Cutaneous Melanoma.
    Song LB; Luan JC; Zhang QJ; Chen L; Wang HY; Cao XC; Song NH; Lu Y
    J Immunol Res; 2021; 2021():6686284. PubMed ID: 33688507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma.
    Hsueh EC; DeBloom JR; Lee JH; Sussman JJ; Covington KR; Caruso HG; Quick AP; Cook RW; Slingluff CL; McMasters KM
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34036233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma.
    Nguyen T; Kuo C; Nicholl MB; Sim MS; Turner RR; Morton DL; Hoon DS
    Epigenetics; 2011 Mar; 6(3):388-94. PubMed ID: 21081840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis.
    Raskin L; Fullen DR; Giordano TJ; Thomas DG; Frohm ML; Cha KB; Ahn J; Mukherjee B; Johnson TM; Gruber SB
    J Invest Dermatol; 2013 Nov; 133(11):2585-2592. PubMed ID: 23633021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study.
    Podlipnik S; Carrera C; Boada A; Richarz NA; López-Estebaranz JL; Pinedo-Moraleda F; Elosua-González M; Martín-González MM; Carrillo-Gijón R; Redondo P; Moreno E; Malvehy J; Puig S
    J Eur Acad Dermatol Venereol; 2019 May; 33(5):857-862. PubMed ID: 30702163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of immune-related genes with prognostic significance in the microenvironment of cutaneous melanoma.
    Qu Y; Zhang S; Zhang Y; Feng X; Wang F
    Virchows Arch; 2021 May; 478(5):943-959. PubMed ID: 33179141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma long non-coding RNA signature predicts prognostic survival and directs clinical risk-specific treatments.
    Chen X; Guo W; Xu XJ; Su F; Wang Y; Zhang Y; Wang Q; Zhu L
    J Dermatol Sci; 2017 Mar; 85(3):226-234. PubMed ID: 27955882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma.
    Gerami P; Cook RW; Wilkinson J; Russell MC; Dhillon N; Amaria RN; Gonzalez R; Lyle S; Johnson CE; Oelschlager KM; Jackson GL; Greisinger AJ; Maetzold D; Delman KA; Lawson DH; Stone JF
    Clin Cancer Res; 2015 Jan; 21(1):175-83. PubMed ID: 25564571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients.
    Greenhaw BN; Covington KR; Kurley SJ; Yeniay Y; Cao NA; Plasseraud KM; Cook RW; Hsueh EC; Gastman BR; Wei ML
    J Am Acad Dermatol; 2020 Sep; 83(3):745-753. PubMed ID: 32229276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translation of a circulating miRNA signature of melanoma into a solid tissue assay to improve diagnostic accuracy and precision.
    Laar RV; King S; McCoy R; Saad M; Fereday S; Winship I; Uzzell C; Landgren A
    Biomark Med; 2021 Sep; 15(13):1111-1122. PubMed ID: 34184547
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.